[Newsmp] In the first half, the Ministry of Food and Drug Safety approved a slightly lower number of clinical trials compared to the corresponding period in the previous year.According to the MFDS information platform (https://nedrug.mfds.go.kr/), 225 companies obtained approvals for 556 clinical tr

[Newsmp] On the 12th, the Ministry of Food and Drug Safety granted approval to Sanofi's Enjaymo (ingredient: sutimlimab) for treating hemolysis in adult patients with cold agglutinin disease.Enjaymo is indicated for hemolytic therapy in adult patients with autoimmune hemolytic anemia (AIHA), a type

[Newsmp] Daiichi Sankyo Korea surpassed KRW 250 billion in annual sales last year, securing the top position in revenue among Japanese pharmaceutical companies operating in Korea.The audit reports showed that Daiichi Sankyo achieved sales of KRW 253.2 billion last year, recording a growth of 3.2% co

[Newsmp] The number of new entries in the patent list of the Ministry of Food and Drug Safety significantly decreased, not exceeding 100 cases during the last six months.According to the MFDS information platform (https://nedrug.mfds.go.kr/), the Ministry of Food and Drug Safety's patent list for th

[Newsmp] Individual investors' net buying amount for Samsung Biologics, among the 47 pharmaceutical index components during the first half of the year, amounted to KRW 336.5 billion, the Korea Exchange said.Daewoong Pharmaceutical exceeded KRW 101.8 billion, surpassing KRW 100 billion, while Green C

[Newsmp] As pharmaceutical and bio companies continue to underperform, the market capitalization of the pharmaceutical index is experiencing a significant decline, jeopardizing the KRW 100 trillion mark.According to the Korea Exchange, the combined market capitalization of the 47 constituent stocks

[Newsmp] Pfizer Pharmaceutical Korea's atopic dermatitis treatment Cibinqo, Kyowa Kirin Korea's hyperphosphatemia treatment Nephoxil, and Novartis Korea's chronic myelogenous leukemia treatment Scemblix were newly listed on the list of drug benefits.Among the existing listed items, Ultomiris (AstraZ

[Newsmp] In the third quarter of last year, the number of patients hospitalized for cancer treatment saw a significant decrease. In the meantime, breast cancer patients outnumbered those with lung cancer.According to the Health Insurance Review and Assessment Service (HIRA), the number of patients w

[Newsmp] The endometrial cancer treatment drug, Jemperli, and the multiple myeloma treatment drug, Xpovio, have passed the cancer disease deliberation committee and established reimbursement criteria.On Wednesday, the Health Insurance Review and Assessment Service (HIRA) disclosed the results of its

[Newsmp] The Ministry of Food and Drug Safety authorized the use of the orphan medication 'Minjuvi (Tafasitamab)' for the treatment of diffuse large B-cell lymphoma on 9 June.Diffuse large B-cell lymphoma is the most common lymphoma, known for its fast progression.In the treatment of diffuse large B

[Newsmp] The emergency use of nine products approved for emergency use in 2020 by the Ministry of Food and Drug Safety for COVID-19 emergency use was terminated on June 1.In response, starting June 2, the Ministry of Food and Drug Safety urged medical institutions to use only officially approved pro

[Newsmp] The market for high-priced drugs like immunotherapies and CAR-T cell therapies remains powerful.Evrysdi (Roche) is gaining momentum in the SMA treatment market, as Spinraza (Biogen) and Zolgensma (Novartis) face a downward trend.Newsmp gathered the sales data of pharmaceuticals, such as che

[Newsmp] Welireg (belzutifan) by MSD Korea received approval from the Ministry of Food and Drug Safety on the 23rd.Welireg has been authorized as a therapy for von Hippel-Lindau (VHL) disease, a condition characterized by the development of multiple tumors, by inhibiting cancer-promoting factor (GIF

[Newsmp] Despite facing a decline in the first quarter, the leading global pharmaceutical companies have showcased a sustained rise in the domain of anticancer drugs.The first quarter reports of global pharmaceutical companies, compiled by Newsmp, indicate that while most firms reported a decline in

[Newsmp] The coverage recognition for the oral immunosuppressant everolimus and the contrast agent iodized oil, used to inhibit the immune system after a transplant, will be expanded.The reimbursement criteria for Tremfya (ingredient: Guselkumab), an IL-23 inhibitor manufactured by Janssen, will be

[Newsmp] Verquvo and Retevmo have received approval for their benefit adequacy and passed the Pharmaceutical Benefit Evaluation Committee of the Health Insurance Review and Assessment Service. Breztri Aerosphere and Jivi have been provisionally recognized.The Health Insurance Review and Assessment S

[Newsmp] In April, while the pharmaceutical index showed signs of recovery by surpassing the 13,000 mark and climbing up to 14,000, there were significant differences among investors.According to the Korea Exchange, institutional investors and foreign investors recorded a net buying amount of KRW 30

[Newsmp] After reducing their donations in the first two years of the COVID-19 pandemic, the Korean subsidiaries of multinational pharmaceutical companies expanded their discretionary spending last year.Newsmp has compiled audit reports for 36 companies' financial statements from September to Decemb

[Newsmp] With the application of health insurance to the combined therapy of SGLT-2 inhibitors and DDP-4 inhibitors, combination drugs that were not previously covered by insurance after their release have all become eligible for coverage.The Ministry of Health and Welfare revised and issued a revis

[Newsmp] In response to COVID-19, the Korean subsidiaries of multinational pharmaceutical companies greatly increased their sales last year.Based on the audit reports of the Korean subsidiaries of multinational pharmaceutical companies in the last quarter of 2022, aggregated by Newsmp, the total sal